Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female infants aged from 6 months to ≤ 12 months included.~* Ability to swallow oral suspension.~* Body weight \>5 kg.~* Uncomplicated malaria, with microscopically confirmed mono-infection by P. falciparum (parasitaemia ≥1000/microL and \<200000/microL).~* History of fever anytime during the preceding 48 hours or presence of fever (axillary temperature ≥37.5 °C or ≥38.0 °C rectally).~* Ability of parents or guardians to understand the nature of the trial and providing signed informed consent.~* Stable residence in the study area during the two months after recruitment and willingness to comply with the study protocol and the study visit schedule.~Exclusion Criteria:~* Antimalarial treatment with amodiaquine, chloroquine, quinine or lumefantrine-based compounds within the previous 6 weeks, with piperaquine-based compound, or mefloquine, or sulphadoxine pyrimethamine within the previous 3 months and with halofantrine within the 30 days prior to screening.~* Any other antimalarial treatment or antibiotics with antimalarial activity (including cotrimoxazol) and any herbal products, within the 7 days prior to screening.~* Severe malnutrition (defined as weight for height \<70% of the median National Center for Health Statistics(NCHS)/WHO reference).~* Severe vomiting or dehydration.~* Presence of jaundice.~* Known hypersensitivity to the artemisinin-based therapy or piperaquine.~* History of relevant clinical allergic reaction of any origin.~* Clinical and/or laboratory features of severe malaria.~* Known moderate/ severe renal or liver insufficiency.~* Evidence of clinically relevant haematological, pulmonary, metabolic-endocrine, neurological, urogenital diseases as judged by the investigator.~* Already diagnosed HIV infection, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.~* Previous admission for, or evidence of symptomatic cardiac arrhythmias or with clinically relevant bradycardia at screening (bpm \< 90).~* Family history of sudden death, or known congenital prolongation of the QT interval, or any clinical condition known to prolong the QT interval.~* ECG abnormality that requires urgent management.~* Any treatment which can induce a lengthening of QT interval.~* Gastrointestinal dysfunction that could alter absorption or motility (i.e. malabsorption syndromes, intestinal sub-occlusion or previous major gastrointestinal surgery).~* Any contraindication to blood sampling.~* Moderate and severe anaemia (Hb \< 7 g/dL).~* Patients who have used any drugs or substances known to be strong inhibitors of Cytochrome P enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior to screening.~* Patients who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes)within 28 days prior to screening.~* Children lactated by HIV positive women who are undergoing treatment with antiretroviral drugs.~* Participation in any investigational drug study during the 30 days prior to screening or previously randomised in the present trial.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Eurartesim dispersible oral tablets (Type: EXPERIMENTAL): Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to \<7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to \< 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
- Eurartesim film coated tablet (Type: ACTIVE_COMPARATOR): Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to \<7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to \< 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).

Based on this trial design, predict the completion outcome and termination type (if applicable).